OLX 07010
Alternative Names: OLX-07010Latest Information Update: 06 Feb 2023
At a glance
- Originator OLIGOMERIX
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Alzheimer's disease; Mild cognitive impairment; Progressive supranuclear palsy
- Preclinical Neurodegenerative disorders
Most Recent Events
- 02 Feb 2023 Phase-I clinical trials in Mild cognitive impairment (In volunteers) in USA (PO) (Oligomerix pipeline; February 2023)
- 02 Feb 2023 Phase-I clinical trials in Progressive supranuclear palsy (In volunteers) in USA (PO) (Oligomerix pipeline; February 2023)
- 20 Jan 2023 Phase-I clinical trials in Alzheimer's disease (In volunteers) in USA (PO) (Oligomerix pipeline; February 2023) (NCT05696483)